Clinical trial · Observational
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Prevalence of non-GC phenotype
- timeFrame
- 12 months: from the end of samples collection to the end of study analysis
- measure
- Prevalence of mutations, copy number abnormalities, and structural variants
- timeFrame
- 12 months: from the end of samples collection to the end of study analysis
- measure
- Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions
- timeFrame
- 12 months: from the end of samples collection to the end of study analysis
- measure
- Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures
- timeFrame
- 12 months: from the end of samples collection to the end of study analysis
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024. 2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material. 3. Availability of the baseline and follow-up annotations Exclusion Criteria: 1. Established immunodeficiency conditions. 2. Secondary CNS localizations of DLBCL 3. Transformed DLBCL
References
Publications (0)
Data not yet available